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nitrofurantoin and piperacillin/tazobactam, all of the antibiotics analysed showed increasing proportions of resistant isolates over time,
which were most prominent for ampicillin (from 25.4% in 1998 to 40% in 2013), cefotaxime (0.1% to 6.7%), ceftazidime (0.3% to 14.2%),
ciproﬂoxacin (4.3% to 16.7%) and trimethoprim/sulfamethoxazole (14.6% to 24.8%). There was a marked increase in extended-spectrum
β-lactamase–positive isolates (0.1% to 6.3%) starting in 2005, with male patients and hospital-related patients showing a higher increase
than female patients and outpatients. Proportions of resistant isolates for most antibiotics were generally higher for male patients and
hospital-related patients. Amikacin, nitrofurantoin and trimethoprim/sulfamethoxazole showed a marked increase in resistance
proportions among male subjects aged 10 to 19 years which were absent for female subjects, indicating a strong modulation potential of
host characteristics.
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E-mail: alexandra.badura@medunigraz.atIntroductionEscherichia coli belongs to the physiological intestinal ﬂora of
both humans and other mammals, and depending on its path-
ogenic properties, it can cause various intestinal and extra-
intestinal infections [1]. E. coli is the leading pathogen causing
bacteremia and urinary tract infections in both hospitalized
patients and outpatients, and it is a common cause of peritonitis
as well as skin and soft tissue infections. It can also lead to sepsisClinical Microbiology and Infection © 2015 European Society of Camong newborns, and it belongs to the most frequent causes of
enteric/diarrhoeal diseases globally [2].
E. coli is a highly versatile microorganism which is able to
easily acquire genetic elements responsible for antimicrobial
resistance. Empirical therapy for E. coli infections has become
increasingly difﬁcult as a result of growing resistance rates to
ﬁrst-line antibiotics [3]. Multi-drug-resistant E. coli producing
extended-spectrum β-lactamases (ESBL) have become a sub-
stantial health issue. The production of ESBL confers resistance
to third-generation cephalosporins and monobactams, but not
to cephamycins and carbapenems; β-lactamase inhibitors usu-
ally remain effective in vitro [4]. The emergence of carbapenem
resistance in E. coli due to metallo- and serine-type carbape-
nemases raises concern for public health at a global level [5].
There are numerous studies presenting antibiotic resistance
data of E. coli and Gram-negative pathogens. However, most ofClin Microbiol Infect 2015; 21: 569.e1–569.e7
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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tance problems [6–11]. Surveillance studies focusing exclu-
sively on E. coli and covering a large number of isolates acquired
over a long period of time are of great importance in order to
specify resistance patterns according to different patient-related
factors and to determine emerging resistance developments.
Here we present what is to our knowledge one of the most
comprehensive antibiotic resistance studies about E. coli from a
speciﬁc region. The aim of the study was to retrospectively
analyse the antibiotic resistance patterns of more than 120 000
clinical E. coli isolates originating from both hospitalized patients
and outpatients from southeast Austria from 1998 to 2013. The
large number of isolates allows statistical analysis of antibiotic
resistance data according to patient location (community,
hospital), age, gender and culture site. Moreover, annual
changes in resistance prevalence are described, with a special
focus on ESBL-producing isolates.Materials and methodsIn this retrospective observational study, antibiotic resistance
patterns of a total of 135 878 clinical E. coli isolates were ana-
lysed. Data were retrieved from the Laboratory of Medical
Bacteriology and Mycology of the Medical University of Graz,
Austria from January 1998 to December 2013. Inpatient iso-
lates origin from our 1500-bed medical university center which
covers all medical disciplines (approximately 85 000 inpatients
per year) and from 24 smaller regional hospitals in the federal
province of Styria. Outpatient isolates origin from medical
practices throughout the federal province of Styria (1.2 million
inhabitants; 16 400 km2). In the case of multiple isolates from
one person in a year showing identical resistance patterns, only
the ﬁrst one was considered. A total of 15 843 isolates were
thus excluded; 120 035 remained and were considered for
statistical analysis. For each isolate, patient-related data (age,
gender), patient location (community/hospital) and culture site
were obtained. Culture sites were subdivided into the following
categories: blood, genital tract, urinary tract, respiratory tract,
wounds and others; patient age was categorized as follows: <1,
1 to 9, 10 to 19, 20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69,
70 to 79 and 80 years.
All isolates had been tested in the routine microbiology
laboratory for antibiotic susceptibilities, in general isolates of
community origin with the disk diffusion method and isolates of
hospital origin automatically using a Vitek 2 system (bio-
Mérieux, Marcy l’Etoile, France). From 1 January 1998 to 31
May 2011, results were interpreted using the criteria recom-
mended by the Clinical and Laboratory Standards Institute
(CLSI), formerly known as National Committee for ClinicalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectLaboratory Standards (NCCLS) [12]. From 1 June 2011, results
were interpreted using the criteria recommended by the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST breakpoint tables v1.2, 2011) in its respective cur-
rent version (http://www.eucast.org/clinical_breakpoints/). For
this retrospective study, resistance to the following 12 antibi-
otics was analysed: amikacin, ampicillin, amoxicillin/clavulanic
acid, cefotaxime, ceftazidime, ciproﬂoxacin, gentamicin, imipe-
nem, meropenem, nitrofurantoin (analysed for urinary tract
isolates only), piperacillin/tazobactam and trimethoprim/sulfa-
methoxazole. Resistant and intermediate resistant isolates were
combined. ESBL phenotype conﬁrmation was done either by
the Etest ESBL screen method using strips with cefotaxime,
ceftazidime and cefepime or an ESBL conﬁrmatory test that
involves testing cefotaxime and ceftazidime alone and in com-
bination with clavulanic acid.
Statistical analysis
For the complete data set, proportions of isolates resistant to
the respective antibiotic were determined for each of the
following covariates: culture site, patient location, age group,
gender, year of isolate acquisition and ESBL phenotype. They
are reported as percentages and frequencies. The proportion of
ESBL-positive isolates was also determined per covariate and is
presented in the same way. Resistance and ESBL trends over
time were inspected graphically on a purely descriptive level
(Figs. 1 and 2).
Additionally, the inﬂuence of the aforementioned covariates
on the proportion resistant was further investigated by multi-
variate logistic regression methods. Each covariate except for
culture site was entered linearly into the model, and no in-
teractions were taken into consideration. To determine the
signiﬁcance of culture site, the full model containing all cova-
riates including culture site was compared to the model without
culture site.p values of <0.05 are considered statistically sig-
niﬁcant. Because all analyses are of an exploratory nature, no
correction for multiplicity was applied. All analyses were car-
ried out for each antibiotic separately. Statistical analysis was
performed by the R software package (version 3.0.1) [13].
Ethics statement
The study was approved by the ethics committee of the Medical
University of Graz (26-238 ex 13/14); patient records were
anonymized and deidentiﬁed before analysis.ResultsIn total, 120 035 clinical E. coli isolates were included in the
statistical analysis. The number of isolates analysed per yearious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 569.e1–569.e7
FIG. 1. Annual proportions of resistant isolates from 1998 to 2013 for selected antibiotics.
FIG. 2. Annual proportions of extended-spectrum β-lactamase–pro-
ducing isolates according to patient gender and localization.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Invaried from 4862 (year 2000) to 10 022 (year 2013) as a result
of a constant increase of patient samples during the investiga-
tion period. The majority of isolates originated from female
patients (79.2%, compared to 20.8% male) and from outpatients
(72.6%, compared to 27.4% hospital related). Among culture
sites, urinary tract (68.4%) was analysed most frequently. Age
groups were roughly evenly distributed among patients, with
less than 1 year of age being the least frequent, at 2.1%
(Supplementary Table 1).
Annual proportions of resistant and ESBL-producing
isolates
Except for amoxicillin/clavulanic acid, nitrofurantoin and
piperacillin/tazobactam, all the antibiotics tested showed
increasing proportions of resistant isolates over time (Fig. 1),
which were most prominent for ampicillin (from 25.4% in 1998
to 40% in 2013), cefotaxime (0.1% to 6.7%), ceftazidime (0.3%
to 14.2%), ciproﬂoxacin (4.3% to 16.7%) and trimethoprim/
sulfamethoxazole (14.6% to 24.8%). Of all 120 035 isolates,
4297 (3.6%) tested positive for ESBL production. Fig. 2 presents
the annual proportions of designated ESBL-producing isolatesfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 569.e1–569.e7
TABLE 1. Proportions of drug-resistant Escherichia coli isolates according to ESBL phenotypea
Drug ESBL negative ESBL positive Difference, OR (95% CI)b
Amikacin 7.4 (8503/115 712) 59.3 (2544/4294) 16.2 (15.1, 17.3)*
Ceftazidime 0.3 (226/67 255) 89.4 (3700/4138) 6 × 104 (4 × 104, 9 × 104)*
Ciproﬂoxacin 10.7 (12 415/115 708) 80.4 (3452/4294) 27.3 (25.1, 29.7)*
Cefotaxime 0.2 (245/114 722) 99.4 (4269/4293) 3 × 103 (3 × 103, 4 × 103)*
Gentamicin 3.2 (3338/103 159) 25.0 (1059/4232) 6.8 (6.2, 7.4)*
Imipenem 0.04 (7/18 576) 0.2 (3/1816) 4 (0.7, 19.7)
Meropenem 0.02 (5/28 362) 0.05 (2/3687) 5.1 (0.7, 28.3)
Nitrofurantoin 1.2 (943/79 108) 9.0 (275/3061) 8.1 (7, 9.5)*
Piperacillin/tazobactam 1.2 (897/76 285) 15.9 (671/4228) 11.7 (10.4, 13.1)*
Trimethoprim/sulfamethoxazole 20.0 (23 103/115 698) 71.2 (3056/4291) 8.2 (7.7, 8.8)*
ESBL, extended-spectrum β-lactamase; OR, odds ratio; CI, conﬁdence interval.
*Signiﬁcantly different (p < 0.05).
aProportions resistant are provided as percentage and frequencies for each group, respectively.
bThe ‘Difference’ column contains ORs adjusted for gender, age as a metric covariate, patient location, year of isolate acquisition and ESBL phenotype for ESBL-positive isolates
compared to ESBL-negative isolates.
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notable increase in ESBL-positive isolates starting in 2005, with
male patients and hospital-related patients showing a higher
increase than female patients and outpatients. Although this
increase could be observed for all age groups, it was most
marked for patients over 60 (Supplementary Fig. 2). Table 1
shows the coresistance rates for ESBL-positive isolates
compared to ESBL-negative isolates. Logistic regression analysis
revealed a signiﬁcantly higher proportion of coresistant isolates
among ESBL-producing isolates for most antibiotics tested
(amikacin, amoxicillin/clavulanic acid, gentamicin, ciproﬂoxacin,
nitrofurantoin, trimethoprim/sulfamethoxazole and piperacillin/
tazobactam).
Proportions of resistant isolates per culture site,
patient location, gender and age
Tables 2 and 3 present the proportion of resistant isolates
according to culture site, gender and patient location for each
antibiotic. Our exploratory analyses showed statistically signif-
icant differences in antibiotic resistances between different
culture sites as well as between community and hospital-relatedTABLE 2. Resistance rates of Escherichia coli by culture sitea
Drug Urinary tract Genital tract
Ampicillin 36.6 (30024/82057) 25.9 (5927/22851)
Amoxicillin/clavulanic acid 9.3 (7620/82054) 4.3 (974/22894)
Amikacin 1.2 (39/3167) 0.02 (4/16326)
Ceftazidime 7.4 (2813/38116) 0.8 (156/18701)
Ciproﬂoxacin 15.4 (12623/82054) 3.4 (781/22888)
Cefotaxime 4.0 (3212/81087) 1.0 (231/22872)
Gentamicin 4.4 (3042/69466) 1.9 (433/22870)
Imipenem 0.02 (1/5671) 0.01 (1/7330)
Meropenem 0.00 (0/8820) 0.00 (0/11567)
Piperacillin/tazobactam 1.7 (788/45677) 0.4 (90/20506)
Trimethoprim/sulfamethoxazole 24.5 (20073/82053) 12.4 (2828/22881)
ESBL, extended-spectrum β-lactamase.
*Signiﬁcantly different (α = 0.05).
aResistance rates are provided as percentage (number resistant/number total).
bThe p values correspond to a chi-squared test result for full versus reduced model, where t
ESBL phenotype and culture site, and the reduced model contains the same parameters exc
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectpatients for all antibiotics, except for imipenem and mer-
openem; and between female and male patients except for
amikacin, imipenem, meropenem and trimethoprim/sulfameth-
oxazole. The overall distribution of resistant isolates for
selected antibiotics (with >1% overall resistance) according
to patient gender and age shows higher resistance rates
throughout for male patients in all age groups, except for <1
year. Proportions of resistant isolates gradually increased with
age for ampicillin, nitrofurantoin and trimethoprim/sulfameth-
oxazole, showing a marked increase for male subjects in the age
group 10 to 19 years (Fig. 3). Ampicillin, cefotaxime, ceftazi-
dime and trimethoprim/sulfamethoxazole additionally increased
markedly with old age (Supplementary Fig. 1).DiscussionThe emergence of antimicrobial resistance among Gram-
negative pathogens is globally regarded as one of the most
pressing public health challenges [14]. Thus, surveillance studies
on antibiotic resistance in these pathogens are of key importanceWound Respiratory tract Blood pb
42.4 (3060/7222) 39.7 (1172/2952) 44.4 (149/336) <0.001*
15.1 (1089/7228) 18.6 (550/2957) 21.1 (71/336) <0.001*
0.6 (37/6313) 1.0 (24/2502) 1.5 (4/265) <0.001*
6.1 (424/6917) 4.6 (132/2859) 2.7 (9/336) <0.001*
18.7 (1351/7230) 14.3 (423/2957) 17.6 (59/336) <0.001*
6.7 (485/7228) 4.7 (140/2955) 4.5 (15/336) <0.001*
5.8 (422/7228) 5.4 (159/2954) 3.6 (12/336) <0.001*
0.09 (3/3351) 0.07 (1/1477) 0.00 (0/226) 0.29
0.04 (2/5533) 0.05 (1/2119) 0.00 (0/309) 0.06
4.6 (317/6890) 6.0 (167/2763) 6.91 (23/333) <0.001*
22.7 (1639/7226) 16.6 (490/2956) 25.3 (85/336) <0.001*
he full model incorporates patient age, gender and location, year of isolate acquisition,
ept for culture site.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 569.e1–569.e7





OR (95% CI)b Community Hospital Difference, OR (95% CI)b
Ampicillin 0.3 (70/23860) 0.9 (76/8721) 1.3 (0.9, 1.8) 0.1 (27/18866) 0.9 (119/13720) 4.9 (3.2, 7.7)*
Amoxicillin/clavulanic acid 33.7 (32028/95011) 41.2 (10263/24917) 1.2 (1.1, 1.2) 33.6 (29254/87144) 39.8 (13049/32808) 1.3 (1.2, 1.3)*
Amikacin 8.1 (7670/95056) 13.5 (3376/24926) 1.3 (1.3, 1.4) 7.7 (6729/87191) 13.2 (4318/32815) 1.6 (1.6, 1.7)*
Ceftazidime 4.7 (2558/54324) 8.0 (1365/17052) 1.4 (1.1, 1.7) 5.3 (2389/45348) 5.9 (1537/26045) 1.4 (1.2, 1.7)*
Ciproﬂoxacin 11.4 (10830/95050) 20.2 (5035/24928) 1.5 (1.5, 1.6) 12.5 (10905/87182) 15.1 (4962/32820) 1.1 (1.0, 1.1)*
Cefotaxime 3.2 (2992/94274) 6.2 (1519/24717) 1.7 (1.3, 2.2) 3.3 (2871/87123) 5.2 (1643/31892) 1.5 (1.1, 1.9)*
Gentamicin 3.4 (2891/84583) 6.6 (1503/22789) 1.6 (1.5, 1.7) 3.7 (2734/74624) 5.1 (1663/32767) 1.2 (1.1, 1.3)*
Imipenem 0.02 (3/14840) 0.1 (7/5550) 3.4 (0.9, 16.5) 0.01 (1/10655) 0.09 (9/9737) 6.8 (1.2, 130.4)
Meropenem 0.00 (1/22460) 0.06 (6/9578) 7.3 (1.2, 138.8) 0.00 (0/15652) 0.04 (7/16397) 2 × 107 (0, NA)
Nitrofurantoin 1.2 (769/66041) 2.8 (449/16109) 2 (1.8, 2.2) 1.4 (853/62735) 1.9 (365/19434) 1.2 (1.1, 1.4)*
Piperacillin/tazobactam 1.5 (909/62115) 3.6 (659/18381) 1.5 (1.4, 1.7) 1.2 (650/54023) 3.5 (918/26490) 2.7 (2.4, 3)*
Trimethoprim/sulfamethoxazole 21.3 (20223/95041) 23.8 (5927/24924) 1 (0.9, 1.0) 21.2 (18446/87173) 23.5 (7713/32816) 1.1 (1.1, 1.2)*
OR, odds ratio; CI, conﬁdence interval.
*Signiﬁcantly different (p < 0.05).
aProportions resistant are provided as percentage and frequencies.
bThe ‘Difference’ column contains ORs adjusted for gender, age as a metric covariate, patient location, year of isolate acquisition and ESBL phenotype for second group compared to
the ﬁrst group.
FIG. 3. Distribution of resistant isolates for ampicillin, trimethoprim/sulfamethoxazole and nitrofurantoin according to patient gender and age.
CMI Badura et al. E. coli resistance in Austria 569.e5to identify changes in current resistance situations, especially in
order to offer, critically review or revise empiric therapy in a
region. The present study analyses one of the largest databases of
resistance in E. coli isolates in Europe over an extensive period of
time, allowing for reliable identiﬁcation of overall trends. More
than 120 000 clinical E. coli isolates from patients in hospital and
community settings of a large metropolitan area in Austria were
analysed regarding their antibiotic resistance patterns to the
most important antimicrobial agents. Because of the lack of
clinical data, no discussion in relation to severity and patient
outcome is possible. Potential bias in the results is possible as a
result of multiple isolates originating from the same patient. This
bias, however, is considered to be of minimal impact because of
the large amount of data analysed.
Within the present study, two different methods for sus-
ceptibility testing were used. Whereas isolates of community
origin were routinely tested using the disk diffusion method,
isolates of hospital origin were routinely tested using the VitekClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and In2 automated instrument providing minimal inhibitory concen-
tration (MIC) results. Both methods have been shown to
produce very similar overall susceptibility category agreements
providing a high degree of comparability (Jorgensen et al.,
personal communication, 2006). During the study period, het-
erogeneous interpretative criteria were implemented, which
may further bias the statistical analysis. The application of the
EUCAST guidelines for antibiotic susceptibility testing of
Enterobacteriaceae was shown by several authors to result in
higher resistance rates reported in E. coli due to lower resis-
tance MIC breakpoints used for certain antibiotics [15,16]. This
artiﬁcial change is, however, not observed for any antibiotic
tested in the present study, indicating that the proportion of
borderline resistant isolates is of little importance for the large
data set analysed. With regard to the analyses of ESBL-
producing isolates, the change from CLSI to EUCAST guide-
lines is of no consequence because ESBL production was
phenotypically conﬁrmed in all isolates. Over the wholefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 569.e1–569.e7
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roquinolones and trimethoprim/sulfamethoxazole increased
markedly. This applied both to community and hospital-related
infections. Regarding resistance to aminopenicillins, third-
generation cephalosporins, ﬂuoroquinolones, aminoglycosides
and carbapenems among invasive E. coli isolates analysed by the
European Antimicrobial Resistance Surveillance Network
(EARS-Net), a continuously increasing trend of antimicrobial
resistance is seen in over a third of the reporting countries
from 2009 to 2012 [2]. In the present study, E. coli isolates
showed consistently low resistance rates to amikacin and car-
bapenems (imipenem, meropenem). Infections caused by
carbapenem-resistant E. coli have increasingly been reported
from other European countries, but in the region of southeast
Austria, they have only occurred rarely until now [5,17–20]. It
should, however, be pointed out that OXA-48-producing E. coli
can still be phenotypically susceptible to carbapenems, which
may risk underestimation of their spread.
Over the last few years, ESBL-producing isolates among
E. coli have globally been found in increasing numbers from
hospitalized patients as well as from community-acquired in-
fections and environmental samples [3,21]. This increase can be
observed not only for countries with generally low resistance
rates but also for countries with comparatively high levels [2].
This is mainly due to a dramatic increase in CTX-M-type en-
zymes [22]. We report here on an overall increase in ESBL-
producing isolates, from 0.1% in 1998 to 6.3% in 2013, with a
slight drop in the last year of observation. Public national and
regional campaigns providing comprehensive information and
thus raising awareness of the importance of proper antimi-
crobial prescription practices, infection prevention and control
are probably the cause of this decline in our region. As pre-
sented from intra-abdominal infections by Hawser et al., ESBL-
producing isolates from the region of southeast Austria showed
signiﬁcantly higher resistance rates to several agents with levels
of coresistance of up to 80% for ciproﬂoxacin and 71% for
trimethoprim/sulfamethoxazole [8]. Our data furthermore
show a continuous increase of ESBL-negative isolates resistant
to cefotaxime and/or ceftazidime over time (data not shown),
indicating that plasmid-mediated AmpC producers are
emerging in our region, albeit at comparatively low level.
The present study analyses one of the largest databases of
resistance patterns of E. coli isolates in Europe. The large
amount of resistance data that was statistically analysed in this
work enabled us to identify relationships between antibiotic
resistance and culture sites. Levels of antimicrobial resistance
varied depending on the culture site, with the lowest rates for
the genital tract group, where E. coli isolates predominantly
occur as commensals. These results are in agreement with the
ﬁndings from two studies [23,24]. Similar to results found inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectSpain and France, proportions of resistant isolates for all anti-
biotics analysed from Austria were markedly higher in hospitals
than in the community setting [23,25]. This seems to conﬁrm
that the issue of antibiotic resistant E. coli is still focused on
hospital-related infections.
As far as the connection between antibiotic resistance rates
and patient gender is concerned, our observations ﬁt with two
previous reports documenting signiﬁcantly higher proportions
in male subjects [23,26]. This difference also proved to be
signiﬁcant in our data for all antibiotics analysed, except for
amikacin and trimethoprim/sulfamethoxazole. For amikacin,
this can be explained by the generally very small number of
resistant isolates. For trimethoprim/sulfamethoxazole, the
large number of isolates analysed in this study from female
patients with urinary tract infections could bias the result as a
result of its frequent therapeutic use. In this study, we docu-
mented a rise in antibiotic resistance rates with patient age for
several of the agents tested, as has been shown previously
[23,26]. In the latter study, the authors showed differences in
the time of acquisition of resistance between male and female
subjects. For the majority of agents tested, and particularly for
ciproﬂoxacin, a remarkable increase in E. coli resistance rates
among male subjects at puberty was found, which was absent
for female subjects. The analysis of E. coli resistance data in the
present study conﬁrms these results. Almost all antibiotics
analysed either showed a sudden increase or the onset of
higher resistance levels among male subjects at the age of 10 to
19 years, indicating a strong modulation potential of host
characteristics.
Austrian antibiotic consumption data showed increased
quinolone and β-lactam/β-lactamase inhibitor combination
consumption from 1998 until 2007 but stable third-generation
cephalosporin between 1998 and 2009 and decreasing
trimethoprim/sulfamethoxazole use from 1999 to 2006 (http://
bmg.gv.at/cms/home/attachments/9/5/3/CH1318/CMS1409576
188223/aures_2012.pdf). Unfortunately, we do not have anti-
biotic consumption data for our speciﬁc southeast Austrian
region or from speciﬁc patients with E. coli isolates. Therefore,
we are not able to correlate antibiotic consumption with spe-
ciﬁc resistance patterns observed in our study.
In conclusion, we report here for the ﬁrst time for Austria
that E. coli resistance data are strongly inﬂuenced by patient
gender, age and location. Further studies, including analysis of
antibiotic resistance data of other genera in correlation with
patient-related data, will be necessary to elucidate interactions
between antibiotic-resistant bacteria with speciﬁc host factors.
Ongoing monitoring studies of overall antibiotic resistance in
E. coli at the local and regional levels are essential in order to
detect alarming resistance mechanisms and to promptly
implement measures to avoid their spread.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 569.e1–569.e7
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